Nasdaq-listed biotech firm MEI Pharma has pledged $100 million to a dedicated Litecoin (LTC) treasury strategy, marking one of the largest corporate allocations to the cryptocurrency to date. The private placement, led by crypto investment firms GSR and Titan Partners, was announced on July 18, 2025, alongside the appointment of Litecoin creator Charlie Lee to MEI Pharma's board of directors.
The Litecoin Foundation has taken a direct stake in MEI Pharma, cementing a strategic partnership between the biotech company and the cryptocurrency ecosystem. This initiative represents the first institutional-level treasury strategy for Litecoin by a public company, driven by LTC's reliability as a low-cost, high-speed payment network with proven utility in cross-border transactions and retail integrations. Charlie Lee emphasized Litecoin's real-world dominance on platforms like BitPay, where it consistently processes more transactions than Bitcoin, stating: "This partnership brings Litecoin's utility into an institutional setting for the first time."
GSR will serve as MEI Pharma's strategic advisor and digital asset treasury manager, with Joshua Riezman, US Chief Strategy Officer at GSR, noting the move reflects rising institutional confidence in Litecoin's credibility and regulatory clarity. The investment consortium includes the Litecoin Foundation, Charlie Lee, GSR, and venture firms such as Parafi, CoinFund, and Delta Blockchain.